Pfizer

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...
Pfizer

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

(NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-t ...
Pfizer

Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO

Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking ...
Pfizer

Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts

To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at ...